Lenvatinib Versus Atezolizumab Plus Bevacizumab as First‐Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi‐Center Retrospective Study
- 13 September 2025
- journal article
- Published by Wiley in Hepatology Research
- Vol. 56 (1) , 100-110
Abstract
Aim: Atezolizumab plus bevacizumab (Atezo+Bev) therapy is the preferred first‐line treatment for advanced hepatocellular carcinoma (HCC). However, the efficacy of Atezo+Bev is limited in patients with a CRAFITY score of 2 (C‐reactive protein ≥ 1 mg/dL and alpha‐fetoprotein [AFP] ≥ 100 ng/mL). This study compared the efficacy and safety of lenvatinib and Atezo+Bev in these patients. Methods: We retrospectively analyzed 774 patients treated with lenvatinib or Atezo+Bev as first‐line treatment for advanced HCC between October 2020 and December 2023 across 11 hospitals in Japan. Among them, 90 patients (11.6%) had a CRAFITY score of 2. Progression‐free survival (PFS), overall survival (OS), disease control rate (DCR), and safety profiles were compared. Results: Baseline characteristics were similar, except tumor size and AFP levels, which were higher in the Atezo+Bev group. Median PFS was significantly longer in the lenvatinib group compared to the Atezo+Bev group (6.0 vs. 2.3 months; hazard ratio [HR]: 0.55, 95% confidence interval [CI]: 0.32–0.95]; p = 0.032). The median OS was not significantly different between the two groups (9.8 vs. 5.2 months; HR: 0.66, 95% CI: 0.41–1.08; p = 0.101). The DCR (62.0% vs. 30.0%; p = 0.003) and the occurrence of grade ≥ 3 treatment‐related adverse events (46.0% vs. 20.0%; p = 0.014) were significantly higher in the lenvatinib group than in the Atezo+Bev group. Conclusion: Lenvatinib provided a significantly longer PFS than Atezo+Bev in patients with HCC and a baseline CRAFITY score of 2, whereas OS did not significantly differ between the two groups. These findings may serve as a cornerstone for developing biomarker‐based strategies in first‐line treatment selection for this patient population.Keywords
This publication has 31 references indexed in Scilit:
- Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaAnnals of Oncology, 2024
- Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinomaCancer Medicine, 2022
- Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT studyJournal of Hepatology, 2022
- Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinibCancer Medicine, 2022
- Immunomodulatory impact of α-fetoproteinTrends in Immunology, 2022
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinomaJournal of Hepatology, 2022
- Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY scoreJournal of Hepatology, 2022
- Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2020
- Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survivalJournal of Hepatology, 2019
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009